Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2023 - 2032

Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2023 - 2032



The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report “Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.

During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.

In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.

The global key market players include Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

Generics

Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

PDE-5 Inhibitors

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Intravenous/ subcutaneous

Inhalational

Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Pulmonary Arterial Hypertension Market Insights
4.1. Pulmonary Arterial Hypertension Market – Route of Administration Snapshot
4.2. Pulmonary Arterial Hypertension Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Cases of Pulmonary Arterial Hypertension (PAH) Facilitate Market Growth
4.2.1.2. Advancement of soluble guanylate cyclase (SGC)-stimulating drugs
4.2.2. Restraints and Challenges
4.2.2.1. Expiration of critical patents
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Pulmonary Arterial Hypertension Market Route of Administration Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Pulmonary Arterial Hypertension Market, by Drug Class
5.1. Key Findings
5.2. Introduction
5.2.1. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
5.3. PDE-5 Inhibitors
5.3.1. Global Pulmonary Arterial Hypertension Market, by PDE-5 Inhibitors, by Region, 2019-2032 (USD Billion)
5.4. Prostacyclin and Prostacyclin Analogs
5.4.1. Global Pulmonary Arterial Hypertension Market, by Prostacyclin and Prostacyclin Analogs, by Region, 2019-2032 (USD Billion)
5.5. SGC Stimulators
5.5.1. Global Pulmonary Arterial Hypertension Market, by SGC Stimulators, by Region, 2019-2032 (USD Billion)
5.6. Endothelin Receptor Antagonists (ERAs)
5.6.1. Global Pulmonary Arterial Hypertension Market, by Endothelin Receptor Antagonists (ERAs), by Region, 2019-2032 (USD Billion)
6. Global Pulmonary Arterial Hypertension Market, by Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
6.3. Generics
6.3.1. Global Pulmonary Arterial Hypertension Market, by Generics, by Region, 2019-2032 (USD Billion)
6.4. Branded
6.4.1. Global Pulmonary Arterial Hypertension Market, by Branded, by Region, 2019-2032 (USD Billion)
7. Global Pulmonary Arterial Hypertension Market, by Route of Administration
7.1. Key Findings
7.2. Introduction
7.2.1. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
7.3. Intravenous/ subcutaneous
7.3.1. Global Pulmonary Arterial Hypertension Market, by Intravenous/ subcutaneous, By Region, 2019-2032 (USD Billion)
7.4. Inhalational
7.4.1. Global Pulmonary Arterial Hypertension Market, by Inhalational, By Region, 2019-2032 (USD Billion)
7.5. Oral
7.5.1. Global Pulmonary Arterial Hypertension Market, by Oral, By Region, 2019-2032 (USD Billion)
8. Global Pulmonary Arterial Hypertension Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
8.3. Pulmonary Arterial Hypertension Market – North America
8.3.1. North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.3.2. North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.3. North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.3.4. Pulmonary Arterial Hypertension Market – U.S.
8.3.4.1. U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.3.4.2. U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.4.3. U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.3.5. Pulmonary Arterial Hypertension Market – Canada
8.3.5.1. Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.3.5.2. Canada.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.5.3. Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4. Pulmonary Arterial Hypertension Market – Europe
8.4.1. Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.2. Europe.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.3. Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.4. Pulmonary Arterial Hypertension Market – UK
8.4.4.1. UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.4.2. UK.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.4.3. UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.5. Pulmonary Arterial Hypertension Market – France
8.4.5.1. France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.5.2. France.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.5.3. France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.6. Pulmonary Arterial Hypertension Market – Germany
8.4.6.1. Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.6.2. Germany.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.6.3. Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.7. Pulmonary Arterial Hypertension Market – Italy
8.4.7.1. Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.7.2. Italy.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.7.3. Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.8. Pulmonary Arterial Hypertension Market – Spain
8.4.8.1. Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.8.2. Spain.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.8.3. Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.9. Pulmonary Arterial Hypertension Market – Netherlands
8.4.9.1. Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.9.2. Netherlands.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.9.3. Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.4.10. Pulmonary Arterial Hypertension Market – Russia
8.4.10.1. Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.4.10.2. Russia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.10.3. Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5. Pulmonary Arterial Hypertension Market – Asia Pacific
8.5.1. Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.2. Asia Pacific.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.3. Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.4. Pulmonary Arterial Hypertension Market – China
8.5.4.1. China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.4.2. China.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.4.3. China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.5. Pulmonary Arterial Hypertension Market – India
8.5.5.1. India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.5.2. India.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.5.3. India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.6. Pulmonary Arterial Hypertension Market – Malaysia
8.5.6.1. Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.6.2. Malaysia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.6.3. Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.7. Pulmonary Arterial Hypertension Market – Japan
8.5.7.1. Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.7.2. Japan.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.7.3. Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.8. Pulmonary Arterial Hypertension Market – Indonesia
8.5.8.1. Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.8.2. Indonesia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.8.3. Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.5.9. Pulmonary Arterial Hypertension Market – South Korea
8.5.9.1. South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.5.9.2. South Korea.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.9.3. South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.6. Pulmonary Arterial Hypertension Market – Middle East & Africa
8.6.1. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.6.2. Middle East & Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.3. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.6.4. Pulmonary Arterial Hypertension Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.6.4.2. Saudi Arabia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.4.3. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.6.5. Pulmonary Arterial Hypertension Market – UAE
8.6.5.1. UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.6.5.2. UAE.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.5.3. UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.6.6. Pulmonary Arterial Hypertension Market – Israel
8.6.6.1. Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.6.6.2. Israel.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.6.3. Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.6.7. Pulmonary Arterial Hypertension Market – South Africa
8.6.7.1. South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.6.7.2. South Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.7.3. South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.7. Pulmonary Arterial Hypertension Market – Latin America
8.7.1. Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.7.2. Latin America.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.3. Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.7.4. Pulmonary Arterial Hypertension Market – Mexico
8.7.4.1. Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.7.4.2. Mexico.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.4.3. Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.7.5. Pulmonary Arterial Hypertension Market – Brazil
8.7.5.1. Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.7.5.2. Brazil.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.5.3. Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
8.7.6. Pulmonary Arterial Hypertension Market – Argentina
8.7.6.1. Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
8.7.6.2. Argentina.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.6.3. Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Bayer
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Gilead Sciences, Inc.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. GlaxoSmithKline
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Johnson & Johnson
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Lupin Pharmaceuticals, Inc.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Sandoz Inc. (Novartis)
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Sun Pharmaceutical Industries, Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Teva Pharmaceutical Industries Ltd.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. United Therapeutics Corporation
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Viatris Inc.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings